Curevac COVID-19 vaccine scale production seen this year: investor

BERLIN- German biotechnology firm Curevac expects to be able to produce the COVID-19 vaccine it is developing at scale by the end of the year, investor Dietmar Hopp told the Handelsblatt business daily on Friday. Curevac is likely to be beaten to market by U.S. rival Moderna and Germany’s Biontech. Hopp said Curevac may also expand its cooperation with Grohmann, a…

BERLIN (Reuters) – German biotechnology firm Curevac expects to be able to produce the COVID-19 vaccine it is developing at scale by the end of the year, investor Dietmar Hopp told the Handelsblatt business daily on Friday.

“We want to make 100 million doses available by the end of the year,” said billionaire Hopp, one of the founders of software company SAP.

He said he expected regulatory approval in spring or summer of 2021, although limited clearance could come this year to vaccinate people doing jobs that put them at risk of catching COVID-19 or regions with high rates of infection.

Curevac is likely to be beaten to market by U.S. rival Moderna and Germany’s Biontech.

“We can’t win this race,” Hopp said. “But we want to win the race to produce the best vaccine and here we have good chances.”

The Tuebingen-based startup, valued at $10 billion after floating last month on Nasdaq, is one of a number of firms developing vaccines based on molecules carrying a genetic code called messenger RNA (mRNA) to treat diseases.

Hopp said Curevac may also expand its cooperation with Grohmann, a subsidiary of Elon Musk’s electric car maker Tesla, in developing so-called RNA printers that would make it possible to decentralise vaccine production.

Musk was in Germany this week and visited Curevac, sparking speculation that he may invest in the company. Hopp earlier dismissed this as “pure fantasy”.

(Reporting by Douglas Busvine; editing by Jason Neely)

ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.